CytomX Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $663 | $5,963 | $18,658 | $50,917 |
Gross Profit | 153 | 5,963 | 18,658 | 50,917 |
EBITDA | -27,422 | -14,037 | -939 | 23,006 |
EBIT | -27,932 | -14,171 | -1,286 | 22,621 |
Net Income | -26,510 | -14,229 | -154 | 23,525 |
Net Change In Cash | 663 | 5,963 | 18,658 | 50,917 |
Free Cash Flow | -23,444 | -15,421 | -15,780 | -21,162 |
Cash | 12,667 | 34,185 | 49,041 | 47,604 |
Basic Shares | 170,186 | 165,004 | 129,075 | 87,150 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $76,201 | $138,103 | $101,214 | $53,163 |
Gross Profit | 76,201 | 138,103 | 101,214 | 53,163 |
EBITDA | -18,188 | 26,763 | -4,309 | -98,892 |
EBIT | -19,564 | 24,995 | -6,484 | -101,335 |
Net Income | -17,368 | 31,869 | -569 | -97,299 |
Net Change In Cash | 76,201 | 138,103 | 101,214 | 53,163 |
Cost of Revenue | 13,671 | |||
Free Cash Flow | -75,807 | -86,541 | -56,875 | -112,528 |
Cash | 12,667 | 38,052 | 17,171 | 193,650 |
Basic Shares | 137,935 | 84,745 | 73,808 | 65,739 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.22 |
2025-09-30 | -$0.09 |
2025-06-30 | -$0.001 |
